AAV1 Viral Vector Capsid Engineering for Adipocyte Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV-based vectors have low transduction efficiency for adipose tissue, particularly for subcutaneous and visceral adipose tissues, even when directly injected into these tissues.
Innovation Solution
Development of AAV1 vectors with specific inserts in the VP1 capsid protein, optimized for tropism to either subcutaneous or visceral adipose tissues, depending on the route of administration, to enhance transduction efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV-based vectors are used for transduction of adipose tissue, then viral vector delivery is achieved, but transduction efficiency is low
Solution Approach 1:
The patent applies local quality by inserting specific peptide sequences (SEQ ID NO: 1-80) at a defined location in the VP1 capsid protein (between amino acids 590 and 601) to create adipose tissue-specific tropism. This localized modification of the capsid structure enables selective binding to adipocytes while maintaining overall vector functionality, directly resolving the low transduction efficiency problem for adipose tissue.
Solution Approach 2:
The patent changes the chemical parameters of the viral capsid by incorporating specific amino acid sequences (SEQ ID NO: 1-80) that alter the surface properties of the AAV1 vector. These parameter changes in the capsid composition enable enhanced recognition and binding to adipocyte surface receptors, thereby improving transduction efficiency specifically for adipose tissue targets.
2Manufacturing precision
If viral vectors are engineered for adipocyte specificity, then transduction specificity for SCAT or VAT is improved, but vector design complexity increases
Solution Approach 1:
The patent segments the capsid protein design by focusing modifications specifically on the VP1 protein at a precise location (between amino acids 590 and 601), while leaving the rest of the viral vector structure unchanged. This segmented approach allows for targeted adipocyte specificity engineering without requiring complex redesign of the entire viral vector system.
Solution Approach 2:
Instead of modifying the viral genome or transduction mechanism to achieve specificity, the patent inverts the approach by modifying the capsid protein surface properties. This inversion simplifies the design process by focusing on the external interface (capsid-adipocyte interaction) rather than internal viral mechanisms, reducing overall vector design complexity while achieving high transduction specificity.
Data Source
Figure 1~2
AI summary
Viral vectors based on adeno-associated virus (AAV), preferably AAV serotype 1 (AAV1), are provided for use in transduction of adipocytes. The viral vectors of the invention have the advantage of being adapted in tropism for adipocytes, wherein the viral vectors especially in use for intraperitoneal administration are optimized for adipocytes residing in SCAT (subcutaneous adipose tissue) or in VAT (visceral adipose tissue), or the viral vectors in use for oral administration are optimized for adipocytes residing in SCAT or in VAT.